PE20060082A1 - Derivados de aminoacidos como mediadores del transporte inverso de colesterol - Google Patents

Derivados de aminoacidos como mediadores del transporte inverso de colesterol

Info

Publication number
PE20060082A1
PE20060082A1 PE2005000657A PE2005000657A PE20060082A1 PE 20060082 A1 PE20060082 A1 PE 20060082A1 PE 2005000657 A PE2005000657 A PE 2005000657A PE 2005000657 A PE2005000657 A PE 2005000657A PE 20060082 A1 PE20060082 A1 PE 20060082A1
Authority
PE
Peru
Prior art keywords
cholesterol
same
mediators
reverse transport
derivatives
Prior art date
Application number
PE2005000657A
Other languages
English (en)
Inventor
Kashinatham Alisala
Igor Nikoulin
Jagadish C Sircar
Victor Charles Vassar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of PE20060082A1 publication Critical patent/PE20060082A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDA A LA ESTRUCTURA I DONDE A, B, C PUEDEN ESTAR EN CUALQUIER ORDEN Y, A ES UN AMINOACIDO O UN ANALOGO DEL MISMO, QUE COMPRENDE UN ACIDO O UN BIOISOSTERO DEL MISMO SELECCIONADO ENTRE -COOH, -SO2H, -SO3H, -PO3H2, ENTRE OTROS; B ES UN AMINOACIDO O ANALOGO DEL MISMO, QUE COMPRENDE UN GRUPO LIPOFILICO; C ES UN AMINOACIDO O ANALOGO DEL MISMO, QUE COMPRENDE UN GRUPO BASICO O UN BIOISOSTERO DEL MISMO SELECCIONADO ENTRE A, B, C, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1, 2, ENTRE OTROS. DICHOS COMPUESTOS SON MEDIADORES DEL TRANSPORTE INVERSO DEL COLESTEROL, UTILES EN EL TRATAMIENTO DE HIPERCOLESTEROLEMIA, ENFERMEDADES CARDIOVASCULARES ASOCIADAS Y OTRAS ENFERMEDADES
PE2005000657A 2004-06-09 2005-06-09 Derivados de aminoacidos como mediadores del transporte inverso de colesterol PE20060082A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57822604P 2004-06-09 2004-06-09
US66736805P 2005-04-01 2005-04-01

Publications (1)

Publication Number Publication Date
PE20060082A1 true PE20060082A1 (es) 2006-02-09

Family

ID=34982204

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000657A PE20060082A1 (es) 2004-06-09 2005-06-09 Derivados de aminoacidos como mediadores del transporte inverso de colesterol

Country Status (15)

Country Link
US (1) US20070004644A1 (es)
EP (1) EP1753782A1 (es)
JP (1) JP2008509228A (es)
KR (1) KR20070029198A (es)
AR (1) AR049081A1 (es)
AU (1) AU2005255013A1 (es)
BR (1) BRPI0511945A (es)
CA (1) CA2568543A1 (es)
IL (1) IL179302A0 (es)
MX (1) MXJL06000068A (es)
NO (1) NO20070140L (es)
PE (1) PE20060082A1 (es)
TW (1) TW200603795A (es)
UY (1) UY28952A1 (es)
WO (1) WO2005123770A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3423166A1 (de) * 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1999003880A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
BR0009520A (pt) * 1999-04-01 2002-06-11 Esperion Therapeutics Inc Composto, método para sintetizar o mesmo, composição, metódos para o tratramento ou prevenção, em um paciente, de doença cardiovascular, dislipidemia, dislipoproteinemia, distúrbio de metabolismo de glucose, doença de alzheimer, sìndrome x ou sìndrome metabólica, septicemia, distúrbio trombótico, distúrbio associado com receptor ativado por proliferador de peroxissoma, obesidade, pancreatite, hipertensão, doença renal, câncer, inflamação, impotência, para reduzir o teor de gordura de carne de gado bovino, e, para reduzir o teor de colesterol de ovos de aves
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
FR2820435B1 (fr) * 2001-02-05 2004-02-27 Genfit S A Procedes d'identification de composes modulant le transport inverse du cholesterol
CN1809590A (zh) * 2003-04-22 2006-07-26 阿文尼尔药品公司 治疗高胆固醇血症的反向胆固醇转动的介质
KR20070043711A (ko) * 2004-06-09 2007-04-25 아바니르 파마슈티컬스 고콜레스테롤혈증과 관련 질환의 치료를 위한 소분자
EP1753724A1 (en) * 2004-06-09 2007-02-21 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases

Also Published As

Publication number Publication date
AU2005255013A1 (en) 2005-12-29
MXJL06000068A (es) 2007-04-10
BRPI0511945A (pt) 2008-01-29
UY28952A1 (es) 2006-01-31
AR049081A1 (es) 2006-06-21
TW200603795A (en) 2006-02-01
IL179302A0 (en) 2007-03-08
NO20070140L (no) 2007-03-07
KR20070029198A (ko) 2007-03-13
US20070004644A1 (en) 2007-01-04
JP2008509228A (ja) 2008-03-27
WO2005123770A1 (en) 2005-12-29
EP1753782A1 (en) 2007-02-21
CA2568543A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
NO20071369L (no) Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
NZ595196A (en) Peptide-based compounds for enzyme inhibition
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE446313T1 (de) Muteine von tränen-lipocalin
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200870164A1 (ru) Лечение вирусного гепатита
PT1049767E (pt) Coelho transgenico que expressa uma lipoproteina (a) humana funcional
AR047529A1 (es) Compuestos de quinolina sustituidos
ATE399014T1 (de) Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
AR049216A1 (es) Derivados heterociclicos como mediadores del transporte inverso del colesterol para el tratamiento de hiperlipidemia y enfermedades cardiovasculares relacionadas
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
ES2125535T5 (es) Mezclas, que contienen isocianatos emulsionables en agua.
PE20050923A1 (es) Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE602004026336D1 (de) Verfahren zur herstellung von lactamen
UY28115A1 (es) Derivados del acido isoftalico
ATE533495T1 (de) Zusammensetzungen zur behandlung von hautkrankheiten gekennzeichnet durch exsudation von serumproteinen
Yoon et al. Establishment of the agriculture and fisheries heritage system in Korea
PE20060082A1 (es) Derivados de aminoacidos como mediadores del transporte inverso de colesterol
UY26179A1 (es) Amidas sustituidas del ácido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporación de adenosina.

Legal Events

Date Code Title Description
FC Refusal